Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMVP Health Care TECELRA Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMVP Health CarePolicy N/A

    Medicare Part B: TECELRA (afamitresgene autoleucel)

    Customize your policy alerts

    Sign up for all MVP Health Care policy alerts

    Know when MVP Health Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Part B prior authorization and coverage for TECELRA, an autologous T-cell immunotherapy, for eligible MVP Health Care Medicare Advantage members with unresectable or metastatic synovial sarcoma.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: TECELRA (afamitresgene autoleucel)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2020
    Next Review DateN/A
    Key ActionSubmit TECELRA requests for prior authorization under HCPCS code Q2057.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Q2057Medical benefit code
    One-time doseCovered administration
    7 daysPost-treatment monitoring
    GFR ≥ 60Renal function
    ECOG 0–1

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Performance status
    4Eligible HLA-A profiles

    Coverage Criteria

    Initial TECELRA Coverage

    TECELRA may be considered for coverage when all of the following are met.

    Initial TECELRA coverage criteria

    • Member and disease eligibility: The member is 18 years of age or older; TECELRA is prescribed by or provided in consultation with an oncologist; the member has unresectable or metastatic synovial sarcoma; the member is positive for HLA-A*02:01P, HLA-A*02:02P, HLA-A*02:03P, or HLA-A*02:06P; the tumor expresses MAGE-A4 as determined by an FDA-approved or cleared companion diagnostic device; the member has received prior systemic chemotherapy; GFR is at least 60 mL/min; and ECOG performance status is 0 or 1.Age ≥ 18; GFR ≥ 60 mL/min; ECOG 0 or 1

      HLA-A*02:05P and other exclusions are addressed separately.

    • Provider attestation and treatment conditions: The provider attests that pregnancy status will be verified before treatment for biological females with reproductive potential; the member will receive lymphodepleting chemotherapy with fludarabine for 4 days and cyclophosphamide for 3 days; and the member will be monitored daily at the healthcare facility for at least 7 days for signs and symptoms of cytokine release syndrome.Fludarabine 4 days; cyclophosphamide 3 days; monitoring ≥ 7 days

      The administering hospital must be appropriately certified to administer TECELRA.

    Coverage for TECELRA is limited to a one-time dose within 6 months. Replacement requests for product that is lost or damaged and repeat administration are not covered. Coverage is also excluded when the member’s age, dose, dosing frequency, or treatment duration is outside FDA-approved package labeling, and eligibility must be confirmed at the time of infusion.

    Coverage is excluded for adults who are heterozygous or homozygous for HLA-A*02:05P, for members who are pregnant, and for members receiving systemic corticosteroids for at least 14 days before leukapheresis and lymphodepletion or receiving prophylactic systemic corticosteroids. Exclusions also apply to recipients of an allogeneic hematopoietic stem cell transplant and members with an active infection or active inflammatory disorder.

    Coding and Clinical Requirements

    Drugs Requiring Prior Authorization Under the Medical BenefitHCPCSCovered
    Q2057TECELRA® (afamitresgene autoleucel) suspension, for intravenous infusion
    Glomerular filtration rate
    Minimum GFR≥ 60 mL/min
    Treatment contextRequired for TECELRA coverage in members with unresectable or metastatic synovial sarcoma
    DocumentationThe member’s GFR must be documented as part of the clinical eligibility submission
    ECOG performance status
    Required statusECOG performance status of 0 or 1
    Treatment contextApplies to members being evaluated for TECELRA coverage
    Documentation

    Provider Requirements and Submission Guidance

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for TECELRA® (afamitresgene autoleucel) administered under the medical benefit. Submit the request to the MVP pharmacy department and verify applicable Medicare Part B guidance; Part D coverage is governed by the MVP Medicare Part D formulary and policies.

    • HCPCS Q2057 — TECELRA® suspension for intravenous infusion.
    • Refer to relevant CMS LCDs, NCDs, and Policy Articles for the most up-to-date Medicare Part B guidance, when available.
    Documentation Required

    Clinical Eligibility Documentation

    Document that the member meets all clinical eligibility requirements before requesting coverage for TECELRA. The request must include member-specific diagnostic, laboratory, HLA, treatment-history, and performance-status documentation.

    • Member is 18 years of age or older.

    Background

    TECELRA (afamitresgene autoleucel) is a MAGE-A4-directed, genetically modified autologous T-cell immunotherapy. It is composed of CD4- and CD8-positive T cells engineered to express an affinity-enhanced T-cell receptor that targets the MAGE-A4 cancer-testis antigen. The patient’s peripheral blood mononuclear cells are collected by leukapheresis, genetically modified, expanded, formulated, and cryopreserved before infusion.

    Definitions

    TECELRA
    ProductTECELRA (afamitresgene autoleucel)
    Immunotherapy typeGenetically modified autologous T-cell immunotherapy
    TargetDirected against the MAGE-A4 cancer-testis antigen
    Cytokine release syndrome (CRS)
    DefinitionA serious immune-mediated reaction associated with TECELRA treatment
    Product warningTECELRA carries a black box warning for cytokine release syndrome
    Monitoring relevanceMembers must be monitored for signs and symptoms of CRS after treatment

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial treatment may be covered when all eligibility, clinical, laboratory, attestation, and treatment-site requirements are met.

    Initial TECELRA treatment: The member is at least 18 years old; treatment is prescribed by or provided in consultation with an oncologist; the diagnosis is unresectable or metastatic synovial sarcoma; an eligible HLA-A genotype is documented; tumor MAGE-A4 expression is documented using an FDA-approved or cleared companion diagnostic device; prior systemic chemotherapy has been received; GFR is at least 60 mL/min; ECOG performance status is 0 or 1; provider attestation is submitted; planned lymphodepleting chemotherapy with fludarabine for 4 days and cyclophosphamide for 3 days is documented; daily monitoring at the healthcare facility for at least 7 days for signs and symptoms of cytokine release syndrome is documented; and administration will occur at a hospital appropriately certified to administer TECELRA.Age ≥ 18; GFR ≥ 60 mL/min; ECOG 0 or 1; fludarabine 4 days; cyclophosphamide 3 days; monitoring ≥ 7 days

    Coverage is limited to a one-time dose within 6 months and is contingent on eligibility at the time of infusion.

    Step Therapy

    StepRequirement
    1Member must have received prior systemic chemotherapy before TECELRA treatment.

    Quantity Limits

    TECELRA
    Dose limitOne-time dose
    Time periodWithin 6 months
    Replacement requestsReplacement for product that was lost or damaged is not covered

    Site of Care

    Billing Rule

    Administer at an authorized hospital outpatient site

    Administer TECELRA in the hospital outpatient setting at an appropriately certified hospital or authorized TECELRA treatment center.

    Policy Summary
    PayerMVP Health Care
    PolicyMedicare Part B: TECELRA (afamitresgene autoleucel)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 1, 2020
    Next Review DateN/A
    Key ActionSubmit TECELRA requests for prior authorization under HCPCS code Q2057.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Clinical RequirementsProvider Requirements and Submission GuidanceBackgroundDefinitionsInitial Therapy CriteriaStep TherapyQuantity LimitsSite of Care
    The performance status must be documented with the clinical eligibility information
    Daily post-infusion monitoring
    Minimum monitoring periodAt least 7 days
    Monitoring scheduleDaily monitoring at the healthcare facility after infusion
    Clinical focusMonitor for signs and symptoms of cytokine release syndrome (CRS)
    Lymphodepleting fludarabine therapy
    Treatment duration4 days
    TherapyLymphodepleting chemotherapy with fludarabine
    AttestationThe provider must attest that the member will receive the planned fludarabine therapy
    Lymphodepleting cyclophosphamide therapy
    Treatment duration3 days
    TherapyLymphodepleting chemotherapy with cyclophosphamide
    AttestationThe provider must attest that the member will receive the planned cyclophosphamide therapy
  1. TECELRA is prescribed by or in consultation with an oncologist.
  2. Diagnosis is unresectable or metastatic synovial sarcoma.
  3. Member is positive for HLA-A*02:01P, HLA-A*02:02P, HLA-A*02:03P, or HLA-A*02:06P; members heterozygous or homozygous for HLA-A*02:05P are excluded.
  4. Tumor expresses the MAGE-A4 antigen, documented by an FDA-approved or FDA-cleared companion diagnostic device.
  5. Member has received prior systemic chemotherapy.
  6. GFR is ≥ 60 mL/min.
  7. ECOG performance status is 0 or 1.
  8. Documentation Required

    Treatment and Monitoring Attestation

    Provide the required provider attestations before treatment. The attestation must confirm reproductive-status verification, the lymphodepleting chemotherapy regimen, and post-infusion monitoring.

    • For biological females with reproductive potential, pregnancy status will be verified before treatment; pregnancy is excluded.
    • Member will receive lymphodepleting chemotherapy with fludarabine for 4 days and cyclophosphamide for 3 days.
    • Member will be monitored daily at the healthcare facility for at least 7 days for signs and symptoms of cytokine release syndrome (CRS).
    • Provider attestation is required.
    Documentation Required

    Authorized Treatment Center

    Confirm that TECELRA will be administered at a hospital appropriately certified and authorized to provide the treatment. The administering facility must meet the TECELRA authorized treatment-site requirements.

    • Use a TECELRA Authorized Treatment Center.
    • Document that the hospital is appropriately certified to administer TECELRA.
    • Verify the treatment site’s authorization before scheduling infusion.
    Denial Risk

    Eligibility, Authorized Facility, and Product Replacement

    Coverage is contingent on the member’s eligibility at the time of infusion and is limited to a single dose. Requests may be denied when eligibility, facility authorization, or product-replacement requirements are not met.

    • TECELRA is approved as a one-time dose within 6 months.
    • Coverage requires continued eligibility at the time of infusion.
    • Replacement product for lost or damaged TECELRA is not covered.
    • Do not administer at a hospital that is not appropriately certified or at an unauthorized treatment site.
    • Requests lacking required clinical documentation or provider attestations may be denied.
    Denial Risk

    Explicit Exclusion Conditions

    Do not request or administer TECELRA under excluded circumstances or outside FDA-approved package labeling. These exclusions apply in addition to the clinical eligibility and authorization requirements.

    • Age, dose, frequency of dosing, or duration of therapy outside FDA-approved package labeling.
    • Repeat administration.
    • Adults who are heterozygous or homozygous for HLA-A*02:05P.
    • Pregnancy.
    • Systemic corticosteroid use for at least 14 days before leukapheresis and lymphodepletion.
    • Prophylactic systemic corticosteroids.
    • Recipients of allogeneic hematopoietic stem cell transplants.
    • Active infections or active inflammatory disorders.